MedTrace Logo

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

NCT01195675 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-07-28

Study results available
· View outcomes & findings →

Summary

The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo

Conditions

  • Healthy

Interventions

DRUG

BI 10773 (low)

single oral dose

DRUG

Moxifloxacin

single oral dose

DRUG

BI 10773 Placebo

2 times single dose

DRUG

BI 10773 (high)

single oral dose

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2010-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01195675 on ClinicalTrials.gov